{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.50","upperLimit":"25.50","value":"20.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"To evaluate the effect of Ixazomib on inducing osteoblast activation as measured by change in serum osteocalcin from baseline to end of study in patients with relapsed/refractory multiple myeloma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.\n\nIxazomib","id":"OG000","title":"Ixazomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline, Treatment (28-day cycles for 6 cycles)","title":"Change in Serum Osteocalcin From Baseline to End of Study in Patients With Relapsed/Refractory Multiple Myeloma.","type":"PRIMARY","unitOfMeasure":"ng/ML"}